NOT on Yahoo - HYBN HYBRIDON, INC. TO PRESENT AT THE WALL STREET ANALYST FORUM'S
- NOT On Yahoo -
49TH INSTITUTIONAL INVESTOR CONFERENCE
9/11/2003 8:00:00 AM
CAMBRIDGE, Mass., Sep 11, 2003 /PRNewswire-FirstCall via COMTEX/ -- Hybridon, Inc.
(OTC Bulletin Board: HYBN.OB) Hybridon, Inc. announced today that Stephen R. Seiler,
Chief Executive Officer, will present an overview of the Company at the Wall Street
Analyst Forum's 49th Institutional Investor Conference at 1:20 p.m. eastern daylight
time on Monday, September 15, 2003. The conference is being held at the Roosevelt
Hotel in New York City. An audio webcast of the presentation can be viewed live and
will be available for 30 days after the conference. Investors may access the webcast
under the Investor Relations section of Hybridon's website at www.hybridon.com.
Hybridon Inc. is a leader in the discovery and development of novel therapeutics
based on synthetic DNA for the treatment of deadly or debilitating diseases such as
cancer, infectious disease and asthma/allergy for which there are no cures or for
which current treatments are inadequate. By using two different drug discovery
platforms, Immune Modulation and Antisense technology, Hybridon can produce multiple
drug candidates and address multiple disease targets.
Hybridon's internal drug development efforts are based on its two lead drug
candidates, HYB2055 and GEM(R)231, both for the treatment of cancer. Hybridon is also
conducting several other internal drug discovery programs, as well as collaborating
with external partners. For more information on Hybridon, visit the Company's website
at hybridon.com. |
